Thailand Cannabis Extract License: What Changes Before 31 December 2026

What the Thailand Cannabis Extract License Now Covers

The regulation applies to cannabis and hemp extracts that contain more than 0.2% tetrahydrocannabinol (THC) by weight. Those extracts remain Category 5 narcotics under Thailand’s Narcotics Code. Anyone who produces, imports, exports, sells, or possesses them needs a licence.

Notably, the new rules cut in two directions at once. On one hand, they widen the permitted purposes. The previous 2021 regulation allowed medical use alone. The 2026 regulation adds three more: research, industrial use, and official narcotics-suppression work by state agencies. On the other hand, they sharply narrow the pool of businesses that may apply.

This distinction matters commercially. Thailand has not closed the extract market. Instead, it has decided who gets to operate in it.

Why Foreign Companies Lose Access

The eligibility rule is the headline change. Licences may be granted only to three classes of applicant:

• Thai juristic persons that do not qualify as “foreign” under the Foreign Business Act B.E. 2542 (1999)
• Government agencies
• The Thai Red Cross Society

Consequently, the definition of “foreigner” in the Foreign Business Act becomes decisive. That definition captures foreign individuals, foreign-incorporated entities, and Thai companies in which foreigners hold half or more of the share capital. A company that has operated comfortably for years may therefore find itself excluded on a shareholding test rather than on anything it has done wrong.

Importantly, this is not a soft policy signal. It is a licensing gate. A majority foreign-owned company cannot apply, however strong its compliance record or capital position.

The Restructuring Question

Some investors will consider reducing foreign shareholding below the statutory threshold. That route deserves careful handling. Thai authorities have intensified nominee-structure enforcement throughout 2026, and a restructuring that exists only on paper invites serious criminal exposure under Section 36 of the Foreign Business Act.

In practice, genuine Thai investment, real capital contribution, and documented commercial substance all matter. Cosmetic ownership changes do not survive scrutiny.

The 31 December 2026 Deadline

Licences issued under the 2020 and 2021 regulations remain valid only until 31 December 2026. After that date, operators must sit within the new framework. As a result, the practical planning window is short.

Firms holding legacy licences should therefore act well before December. Renewal is not automatic, and an applicant that no longer meets the eligibility test cannot simply extend.

Extracts Versus Flower: Two Separate Regimes

Thailand regulates cannabis extracts and cannabis flower under different statutes, and the two regimes moved separately in 2026. High-THC extracts sit under the Narcotics Code. Cannabis flower remains a controlled herb under the Protection and Promotion of Thai Traditional Medicine Knowledge Act B.E. 2542 (1999).

A second ministerial regulation, effective 30 April 2026, tightened the flower framework. It added premises-ownership requirements, dedicated storage standards, qualified-personnel rules, mandatory DTAM training, and odour and smoke control obligations. We cover that instrument in detail in our guide to the Thailand cannabis licence rules under Regulation No. 2.

Crucially, the flower regulation does not impose the same express foreign-ownership bar. Foreign investors may therefore retain a pathway in flower-related activities that has closed for extracts. Even so, the Foreign Business Act, sector rules, and practical premises and staffing requirements still apply.

What This Signals About Thai Regulatory Direction

Thailand decriminalised cannabis in 2022 and attracted substantial foreign capital into a fast-moving commercial market. Since then, policy has steadily reversed toward a controlled, professionalised model. The 2026 regulations continue that trajectory.

Notably, this is not recriminalisation. Cannabis remains lawful in defined forms and for defined purposes. However, the state has reasserted control over who participates and on what terms. Similar tightening has occurred with other controlled botanicals, as our analysis of Thailand’s kratom laws and licensing regime illustrates.

For investors, the lesson generalises beyond cannabis. In sensitive Thai sectors, an early liberalisation window often narrows once the regulatory framework matures. Businesses that build on the assumption of permanent openness carry real structural risk.

Practical Steps for Affected Businesses

Operators should work through a structured review rather than wait for the deadline. We recommend the following sequence:

1. Map every activity by product and THC level. Separate extracts above 0.2% THC from flower and from low-THC products. Each category attracts a different regime.
2. Test your shareholding against the Foreign Business Act definition. Calculate the position precisely, including indirect holdings and any preference-share arrangements.
3. Audit your licence portfolio and expiry dates. Identify which permits fall away on 31 December 2026.
4. Assess whether restructuring is genuinely available. Where it is, document the commercial substance thoroughly from the outset.
5. Model the exit or pivot scenario. If eligibility cannot be achieved lawfully, plan a supply, licensing, or joint-venture alternative early.
6. Review contracts for regulatory-change clauses. Offtake agreements and supply contracts may need renegotiation before year-end.

Companies entering the market for the first time should resolve the ownership question before incorporation. Our team addresses this at the structuring stage through company registration in Thailand, which is considerably cheaper than restructuring later.

Frequently Asked Questions

Conclusion

The Thailand cannabis extract license regime has shifted from an open commercial market to a controlled framework built around Thai-controlled operators. Foreign investors holding legacy licences have until 31 December 2026 to establish a lawful position. That period is short, and the available responses — genuine restructuring, a pivot to flower or low-THC activity, a joint venture, or an orderly exit — all require lead time and careful documentation.

Businesses that treat this as a compliance formality risk losing licensed operations entirely at year-end. Those that address it now retain choices.

Further reference: the Thai Food and Drug Administration administers narcotics licensing, while the Department of Thai Traditional and Alternative Medicine oversees the controlled-herbs framework for cannabis flower.